UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 4, 2004
RIGEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
||
(State or other jurisdiction of incorporation) |
||
|
|
|
0-29889 |
|
94-3248524 |
(Commission File No.) |
|
(IRS Employer Identification No.) |
|
|
|
1180 Veterans Boulevard |
||
(Address of principal executive offices and zip code) |
||
|
|
|
Registrants telephone number, including area code: (650) 624-1100 |
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On May 4, 2004, Rigel Pharmaceuticals, Inc. publicly disseminated a press release announcing certain financial results for the quarter ended March 31, 2004. The foregoing description is qualified in its entirety by reference to Rigels press release dated May 4, 2004, a copy of which is attached hereto as Exhibit 99.1.
The information in this report, including the exhibit hereto, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Rigel Pharmaceuticals, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
RIGEL PHARMACEUTICALS, INC. |
||
|
|
|
|
|
|
|
|
Dated: May 10, 2004 |
|
|
|
|
|
|
|
|
By: |
/s/ James H. Welch |
|
|
|
James H. Welch |
|
|
|
Vice President, Chief Financial Officer and Secretary |
3
EXHIBIT INDEX
Number |
|
Description |
|
|
|
99.1 |
|
Press Release entitled Rigel Announces First Quarter 2004 Financial Results, dated May 4, 2004. |
4